Microbiotica Closes £36M Series C Round

Microbiotica has raised £36 million in Series C funding, according to a FinSMEs report on the deal.

The round marks the company's third major private financing and one of the larger biotech checks landed in the microbiome therapeutics space this cycle. FinSMEs reported the figure as a completed Series C raise, positioning Microbiotica among the select group of UK-based microbiome players to push past a Series C at all.

What do we know about the round?

The reported facts are sparse but concrete:

• Amount: £36 million
• Stage: Series C
• Company: Microbiotica
• Reported by: FinSMEs

FinSMEs did not name the investors, disclose a post-money valuation, or specify a intended use of proceeds in its report. That leaves the £36 million figure as the anchor fact of the deal — and it's a meaningful one.

Why does £36 million matter?

Series C is where biotech financings get serious. Companies reaching this stage have typically cleared early clinical or platform-validation hurdles, and investors writing Series C checks are underwriting later, costlier phases of development.

For a microbiome-focused developer, £36 million buys real runway. The field has had a bruising decade — several high-profile microbiome programs have failed in late-stage trials, and capital for the sector tightened sharply after 2021's biotech downturn. A fresh £36 million commitment signals that at least one set of investors still sees a path to value here.

What's the competitive context?

Microbiotica operates in microbiome-based drug discovery, a sector that has consolidated considerably since its funding peak. Fewer players are now raising later-stage rounds, which makes any Series C in the space notable.

The UK has worked to keep its microbiome and life-sciences pipeline funded through vehicles like British Patient Capital, though FinSMEs' report did not specify which backers participated in this round. The company's name has previously surfaced in UK biotech coverage, but the report itself sticks to the headline facts: the company, the amount, the stage.

What comes next?

Expect follow-on detail within days. Series C announcements usually trail the actual close, and investor syndicates, lead backers and trial-advance plans typically surface in the fuller release. For now, the market has the number that matters: £36 million, Series C, Microbiotica — a data point suggesting the microbiome funding winter may be thawing, at least for companies that have made it this far.